RS-TRANS-4-CHLORO-N-ISOBUTYL-N-(4-METHYLBENZYL)PENT-2-ENAMIDE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	MHQOIEWKBNOIDG-JXMROGBWSA-N
Smiles	CC(C)CN(Cc1ccc(C)cc1)C(=O)\C=C\C(C)Cl
InChI	InChI=1S/C17H24ClNO/c1-13(2)11-19(17(20)10-7-15(4)18)12-16-8-5-14(3)6-9-16/h5-10,13,15H,11-12H2,1-4H3/b10-7+

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C17H24ClNO
Molecular Weight	293.83
AlogP	4.43
Hydrogen Bond Acceptor	1.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	6.0
Polar Surface Area	20.31
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	20.0

Assay Description	Organism	Bioactivity
Light dependent herbicidal activity against Echinochloa oryzicola seedlings assessed as inhibition of seedlings growth at 10 ppm measured after 6 days post compound application under greenhouse conditions at 25 +/- 2 degC with day light	Echinochloa oryzicola	None
Herbicidal activity against Echinochloa oryzicola seedlings assessed as induction of seedlings damage measured after 3 weeks post compound application through paddy water	Echinochloa oryzicola	125.0 gAi/ha
Herbicidal activity against Echinochloa oryzicola grown in greenhouse at 28 degC under sunshine in day time assessed as inhibition of shoot elongation measured after 7 days post compound application	Echinochloa oryzicola	776247.12 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2269170
PubChem	13101257

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).